Toppling high-grade pulmonary neuroendocrine tumors with a DLL3-targeted trojan horse
Open Access
- 22 December 2015
- journal article
- editorial
- Published by Taylor & Francis in Molecular & Cellular Oncology
- Vol. 3 (2) , e1101515
Abstract
Delta-like protein 3 (DLL3) is a novel and tractable tumor-initiating cell-associated target for the antibody-drug conjugate SC16LD6.5 in high-grade pulmonary neuroendocrine tumors. Elevated expression of DLL3, an inhibitor of Notch pathway activation, marks the second recent observation that impairment of Notch receptor signaling may play a critical role in neuroendocrine tumorigenesis.Keywords
This publication has 11 references indexed in Scilit:
- A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivoScience Translational Medicine, 2015
- Comprehensive genomic profiles of small cell lung cancerNature, 2015
- O-Fucosylation of DLL3 Is Required for Its Function during SomitogenesisPLOS ONE, 2015
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancerNature Communications, 2015
- Different assemblies of Notch receptors coordinate the distribution of the major bronchial Clara, ciliated and neuroendocrine cellsDevelopment, 2012
- Novel strategies for the treatment of small-cell lung carcinomaNature Reviews Clinical Oncology, 2011
- Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosisHuman Molecular Genetics, 2010
- Neuroendocrine tumors of the lung: an update.Archives of Pathology & Laboratory Medicine, 2010
- Achaete-Scute Complex Homologue 1 Regulates Tumor-Initiating Capacity in Human Small Cell Lung CancerCancer Research, 2009
- An achaete-scute homologue essential for neuroendocrine differentiation in the lungNature, 1997